B-cell receptors and antibodies specific for type II collagen (Anti-CII BCR/Ab)

B-cell receptors (BCRs) and antibodies specific for type II collagen (CII) are central components in the development of autoimmune joint diseases, most notably rheumatoid arthritis (RA) [Burkhardt et al., 2002, Rheumatol Int]. Type II collagen is the predominant protein in articular cartilage, and the breakdown of self-tolerance leads to the activation of B-cells that recognize CII epitopes [Nandakumar et al., 2003, Arthritis Res Ther]. These activated B-cells produce anti-CII autoantibodies that deposit on joint surfaces, forming immune complexes that activate the complement system and recruit inflammatory cells [Cook et al., 1996, J Invest Med]. This localized inflammatory response causes the release of proteases and cytokines, leading to progressive cartilage erosion and bone destruction. Therapeutic interventions targeting this axis range from broad B-cell depletion using agents like rituximab, which targets the CD20 antigen on B-cells [Edwards et al., 2004, N Engl J Med]. More specific experimental strategies, such as Chimeric Autoantibody Receptor (CAART) T-cells, aim to selectively target and eliminate only the B-cells expressing anti-CII BCRs [Ellebrecht et al., 2016, Science]. This precision approach could potentially offer a more targeted treatment with fewer side effects compared to systemic immunosuppression. Monitoring anti-CII antibody titers serves as a valuable biomarker for disease activity and treatment response in affected patients [Mullazehi et al., 2006, Ann Rheum Dis].

Other names

Anti-CII antibodiesType II collagen-specific B-cell receptorsAnti-collagen type II autoantibodiesCII-specific BCR

The primary mechanism involves the depletion of B-cell populations (e.g., via anti-CD20 therapy) or the suppression of autoantibody production to mitigate cartilage-specific immune attacks and subsequent joint destruction [Edwards et al., 2004, N Engl J Med; Nandakumar et al., 2003, Arthritis Res Ther].